Introduction {#tca12880-sec-0005}
============

As cancer survival rates have improved commensurate with advancements made in cancer diagnosis and treatment methods, the number of patients with recurrent or metastatic cancer continues to increase.[1](#tca12880-bib-0001){ref-type="ref"} The development of effective chemotherapy regimens and combinations of systemic and local treatments has improved the prognosis of metastatic cancer patients.[2](#tca12880-bib-0002){ref-type="ref"}, [3](#tca12880-bib-0003){ref-type="ref"} After the concept of oligometastases was proposed, several studies have reported that aggressive local treatment of oligometastatic lesions may improve patient survival.[4](#tca12880-bib-0004){ref-type="ref"}, [5](#tca12880-bib-0005){ref-type="ref"}, [6](#tca12880-bib-0006){ref-type="ref"}, [7](#tca12880-bib-0007){ref-type="ref"} For example, the National Comprehensive Cancer Network guideline recommends local treatment for pulmonary metastases arising from colon cancer.[8](#tca12880-bib-0008){ref-type="ref"}

However, the criteria for selecting the patients for whom local treatment is appropriate have not yet been defined, particularly as metastatic cancer patients usually experience distant site failure.[9](#tca12880-bib-0009){ref-type="ref"}, [10](#tca12880-bib-0010){ref-type="ref"}, [11](#tca12880-bib-0011){ref-type="ref"} In some patients, local treatment may result in increased toxicity without improved therapeutic outcomes.[12](#tca12880-bib-0012){ref-type="ref"} Therefore, the optimal local therapy remains unclear.[13](#tca12880-bib-0013){ref-type="ref"}, [14](#tca12880-bib-0014){ref-type="ref"}, [15](#tca12880-bib-0015){ref-type="ref"} Surgery is considered the first choice among local treatment modalities, and several studies have shown good local control and survival outcomes in patients with hepatic and pulmonary metastases treated with surgery.[16](#tca12880-bib-0016){ref-type="ref"}, [17](#tca12880-bib-0017){ref-type="ref"} Although stereotactic body radiotherapy (SBRT) is usually recommended for medically inoperable patients, SBRT has shown treatment outcomes similar to surgery, exhibiting high local control and equivalent toxicity profiles.[18](#tca12880-bib-0018){ref-type="ref"}

As is difficult to compare treatment outcomes of SBRT versus metastasectomy in prospective randomized trials, we retrospectively compared the efficacy of these methods as local treatment for pulmonary metastases. Additionally, we aimed to identify the patients who are most likely to benefit from local treatment.

Methods {#tca12880-sec-0006}
=======

Patients {#tca12880-sec-0007}
--------

The Institutional Review Board (IRB) of Gyeongsang National University Hospital (GNUH IRB 2017‐08‐009) approved the study. The inclusion criteria were as follows: (i) the presence of up to three pulmonary metastases arising from any non‐hematological malignancy; (ii) Eastern Cooperative Oncology Group performance status (ECOG PS) 0--2; (iii) surgery or radiotherapy had been performed with ablative intent; and (iv) no previous history of thoracic radiotherapy. Between January 2010 and June 2016, 51 patients who satisfied the selection criteria were identified. Data on patients' clinical characteristics were obtained from electronic medical records. The characteristics of the pulmonary metastatic lesions including size, location, number, the interval from primary tumor diagnosis to the detection of pulmonary metastasis, whether the primary tumor and other metastatic lesions were controlled, and whether the pulmonary metastatic lesion was solitary, were recorded. Complications related to SBRT or surgery were also noted.

Treatment {#tca12880-sec-0008}
---------

A multidisciplinary tumor board decided the treatment modality for each patient. Twenty‐one patients received SBRT for 29 pulmonary metastatic lesions. Three fiducial markers were implanted around the individual peritumoral area under computed tomography (CT)‐guidance for daily set‐up and tumor motion tracking. One week later, planning CT with contrast enhancement was obtained with a patient‐specific immobilization device (Vac‐lok, CIVCO Inc., Kalona, IA, USA) while maintaining regular breathing. Four‐dimensional CT was performed using the Philips Brilliance 16 CT scanner while synchronizing the respiration signal obtained using a monitoring device (Philips pneumatic belt; Philips, Amsterdam, Netherlands). The gross tumor volume (GTV) was the metastatic lung tumor, and was delineated at maximum exhalation (referred to as a 50% phase in our CT scanning system). The clinical target volume (CTV) was the same as the GTV. The primary planning target volume (PTV) was generated by adding a 3 mm setup margin to the CTV. SBRT was performed using the CyberKnife system (Accuray, Sunnyvale, CA, USA); the radiation dose was prescribed to the isodose line covering the entire GTV and more than 95% of the PTV. The total radiation dose was 60 Gy/3 fractions for peripheral lesions and 48 Gy/4 fractions for central lesions. Thirty patients underwent surgical resection for 30 pulmonary metastatic lesions, 28 (93.3%) underwent wedge resection, and 2 (3.9%) underwent lobectomy. Under general anesthesia, a mini‐thoracotomy or video‐assisted thoracoscopic surgery was performed while the patient received single‐lung ventilation using a double lumen endotracheal tube. After lung tissue resection, the chest tube was inserted into the pleural cavity until air leakage ceased and pleural fluid drainage decreased below 150 mL per day.

Statistics {#tca12880-sec-0009}
----------

Overall survival (OS) was defined as the period between the date of first SBRT or surgery and the date of death from any cause. Progression‐free survival (PFS) was defined as the interval from the start of any local treatment to the date of tumor recurrence or death. For SBRT, local recurrence was defined as recurrence in or adjacent to the PTV; for surgery, it was defined as recurrence at or adjacent to the surgical bed. Chi‐squared or Fisher\'s exact tests were used to compare categorical variables between the treatment groups, while the Mann--Whitney *U* test was used to compare continuous variables. We performed univariate and multivariate Cox proportional hazards analyses to evaluate the effect of variables on local control, PFS, and OS. The Kaplan--Meier method was used to calculate the OS and PFS rates, while differences in survival outcomes were assessed using the log‐rank test. Toxicities were recorded according to Common Terminology Criteria for Adverse Events version 4.0. All statistical analyses were performed using SPSS version 20 (IBM Corp., Armonk, NY, USA). *P* \< 0.05 was considered significant.

Results {#tca12880-sec-0010}
=======

Patient and tumor characteristics {#tca12880-sec-0011}
---------------------------------

The patient and treatment characteristics are shown in Table [1](#tca12880-tbl-0001){ref-type="table"}. There were no differences between the treatment groups in terms of gender, age, smoking history, ECOG PS, comorbidities, pulmonary function, interval between primary diagnosis and detection of pulmonary metastases, or tumor location (central vs. peripheral). Comorbidities included hypertension (12 patients), diabetes mellitus (10 patients), cardiovascular disease (8 patients), hepatic disease (6 patients), and other cancer (5 patients). The median tumor size was larger in the SBRT than in the metastasectomy group (2.5 vs. 1.25 cm; *P* = 0.015). Patients with synchronous metastases were more likely to be treated with SBRT than with metastasectomy (*P* = 0.006). There was no significant difference between the groups in terms of achieving control of the primary and metastatic lesions (*P* = 0.722). Systemic chemotherapy after local treatment was more frequently administered in the metastasectomy group (*P* = 0.034).

###### 

Patients and treatment characteristics

  Characteristics                        All               Surgery             SBRT          *P*
  ------------------------------ ------------------- ------------------- ----------------- -------
  Patients number                        51                  30                 21           ---
  Tx site number                         ---                 30                 29           ---
  Gender                                                                                   
  Male                               28 (54.9%)          16 (53.3%)         12 (57.1%)      0.788
  Female                             23 (45.1%)          14 (46.7%)          9 (42.9%)       ---
  Age (years)                        67 (28--85)         63 (28--78)        69 (35--85)     0.236
  Smoking history                                                                          
  None                               37 (72.5%)          19 (63.3%)         18 (85.7%)      0.062
  Ex‐smoker                          11 (21.6%)            9 (30%)           3 (14.3%)       ---
  Current smoker                      2 (3.9%)            2 (6.7%)            0 (0%)         ---
  ECOG PS                                                                                  
  0                                  15 (29.4%)            9 (30%)           6 (28.6%)      0.436
  1                                  30 (58.8%)          19 (63.3%)         11 (52.4%)       ---
  2                                   6 (11.8%)           2 (6.7%)            4 (19%)        ---
  Comorbidities                                                                            
  None                               18 (35.3%)           8 (26.7%)         10 (47.6%)      0.123
  Yes                                33 (64.7%)          22 (73.3%)         11 (52.4%)       ---
  Pulmonary function                                                                       
  FEV1 (L)                        2.39 (1.39--4.37)   2.42 (1.39--4.37)   2.2 (1.59--3.4)   0.640
  FEV1/FVC (%)                      76.3 (54--87)       75.6 (62--87)      79.4 (54--86)    0.596
  Primary cancer                                                                           
  Colorectal                         18 (35.3%)           12 (40%)           6 (28.6%)      0.942
  Hepatobiliary                       7 (13.7%)           2 (6.7%)           5 (23.8%)       ---
  NSCLC                               6 (11.8%)           4 (13.3%)          2 (9.5%)        ---
  Breast                              4 (7.8%)             3 (10%)           1 (4.8%)        ---
  RCC                                 4 (7.8%)            2 (6.7%)           2 (9.5%)        ---
  Esophagus                           3 (5.9%)            1 (3.3%)           2 (9.5%)        ---
  Stomach                             2 (3.9%)            1 (3.3%)           1 (4.8%)        ---
  Others                              7 (13.7%)           5 (16.7%)          2 (9.5%)        ---
  Time interval (months)             30 (1--204)         30 (1--135)        27 (5--204)     0.751
  Location                                                                                 
  Central                             9 (17.6%)           5 (16.7%)           4 (19%)       0.778
  Peripheral                         39 (76.5%)           24 (80%)          15 (71.4%)       ---
  Both                                3 (5.9%)            1 (3.3%)           2 (9.5%)        ---
  Tumor size (cm)                  1.5 (0.6--12.4)     1.25 (0.6--3.3)    2.5 (0.6--12.4)   0.015
  Synchronous Other metastases                                                             
  None                               33 (64.7%)           24 (80%)           9 (42.9%)      0.006
  Yes                                18 (35.3%)            6 (20%)          12 (57.1%)       ---
  Chemotherapy                                                                             
  No                                 41 (80.4%)           21 (70%)          20 (95.2%)      0.034
  Yes                                10 (19.6%)            9 (30%)           1 (4.8%)        ---

ECOG PS, Eastern Cooperative Oncology Group performance status; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; NSCLC, non‐small cell lung cancer; RCC, renal cell carcinoma; SBRT, stereotactic body radiotherapy.

Treatment outcome {#tca12880-sec-0012}
-----------------

The patients were followed up for a median duration of 13.7 months (range: 7.8--75.5). Among the 51 patients, 6 (11.8%) experienced local recurrence, including 4 (19%) in the SBRT group and 2 (6.7%) in the metastasectomy group. The one and two‐year local control rates were 83.5% and 75.2% in the SBRT group and 96.6% and 91.5% in the metastasectomy group, respectively; there were no significant differences between the groups (*P* = 0.163). PFS was significantly longer in the metastasectomy group than in the SBRT group (*P* = 0.02). The one‐year PFS rates were 23.8% and 51.1% in the SBRT and metastasectomy groups, while the corresponding two‐year PFS rates were 11.9% and 46%, respectively. Furthermore, the one and two‐year OS rates were 79.5% and 68.2%, in the SBRT group and 95% and 81.8% in the metastasectomy group, respectively. However, the difference in OS between the treatment groups was not significant (*P* = 0.534).

Univariate analysis showed that age, gender, comorbidities, ECOG PS, interval between diagnosis and lung metastases, tumor size, other synchronous metastases, and treatment modality had no significant influence on local control. However, a larger metastatic mass and the presence of other synchronous metastases were related to poorer PFS (both *P* = 0.001) (Table [2](#tca12880-tbl-0002){ref-type="table"}). Patients treated with SBRT had poorer PFS rates than those who underwent metastasectomy (*P* = 0.024). Tumor size and the presence of synchronous metastases were also risk factors for poor OS (*P* = 0.004 and *P* = 0.040, respectively). The type of treatment modality did not influence OS (*P* = 0.537). The factors identified by univariate analysis and those suggested in previous studies to be related to PFS and OS were subjected to multivariate analysis. This analysis revealed that the presence of other synchronous metastases was the most significant factor associated with poor PFS (hazard ratio \[HR\] 3.461, 95% confidence interval \[CI\] 1.720--6.964; *P* = 0.001), while tumor size was the most significant factor associated with OS (HR 1.386, 95% CI 1.107--1.735; *P* = 0.004). However, the type of treatment (SBRT vs. metastasectomy) did not influence PFS or OS.

###### 

Univariate and multivariate analyses of clinical factors associated with PFS and OS of patients receiving SBRT versus metastasectomy

  Characteristics                   PFS             OS                                                                                           
  ------------------------ ---------------------- ------- ---------------------- ------- ----------------------- ------- ----------------------- -------
  Gender                                                                                                                                         
  Female                                                                                                                                         
  Male                      1.879 (0.938--3.765)   0.075           ---             ---    1.837 (0.517--6.525)    0.347            ---             ---
  Age (years)               1.007 (0.98--1.035)    0.599           ---             ---    0.998 (0.949--1.050)    0939             ---             ---
  ECOG PS                                                                                                                                        
  0                                                                ---             ---                                             ---             ---
  1                         1.367 (0.582--3.21)    0.473           ---             ---    2.45 (0.299--20.073)    0.404            ---             ---
  2                         2.571 (0.807--8.197)   0.110           ---             ---    2.599 (0.232--29.113)   0.439            ---             ---
  Comorbidities                                                                                                                                  
  None                                                             ---             ---                                             ---             ---
  Yes                       1.612 (0.778--3.338)   0.199           ---             ---    0.883 (0.249--3.136)    0.848            ---             ---
  Time interval (Months)    0.997 (0.988--1.005)   0.446           ---             ---    0.999 (0.985--1.014)    0.939            ---             ---
  Tumor size (cm)           1.216 (1.082--1.367)   0.001   1.122 (0.982--1.281)   0.091   1.386 (1.107--1.735)    0.004   1.386 (1.107--1.735)    0.004
  Synchronous metastases                                                                                                                         
  None                                                                                                                                           
  Yes                       3.461 (1.72--6.964)    0.001   3.461 (1.720--6.964)   0.001   3.894 (1.065--14.236)   0.040   2.520 (0.575--11.053)   0.220
  Disease controlled                                                                                                                             
  No                                                               ---             ---                                             ---             ---
  Yes                       0.484 (0.217--1.081)   0.077           ---             ---    0.492 (0.126--1.920)    0.307            ---             ---
  Treatment                                                                                                                                      
  SBRT                                                             ---             ---                                             ---             ---
  Metastasectomy            0.457 (0.232--0.90)    0.024   0.798 (0.354--1.798)   0.586   0.675 (0.194--2.349)    0.537   1.583 (0.313--8.000)    0.579
  Chemotherapy                                                                                                                                   
  No                                                               ---             ---                                             ---             ---
  Yes                       0.673 (0.259--1.750)   0.417           ---             ---     1.86 (0.475--7.275)    0.373            ---             ---

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; SBRT, stereotactic body radiotherapy.

We performed stratification analysis of survival rates according to treatment modality and the presence of synchronous metastases. In patients who received SBRT, those with synchronous metastases tended to have poorer PFS rates (*P* = 0.062) (Fi[1](#tca12880-fig-0001){ref-type="fig"}a), while in patients who underwent metastasectomy, the corresponding difference in PFS was significant (*P* = 0.038) (Fig [1](#tca12880-fig-0001){ref-type="fig"}b). Among patients with no synchronous metastases, there was no significant difference in PFS between the treatment modalities (*P* = 0.327) (Fig [1](#tca12880-fig-0001){ref-type="fig"}c). Similarly, patients with synchronous metastases exhibited no difference in PFS regardless of whether they underwent SBRT or metastasectomy (*P* = 0.727) (Fig [1](#tca12880-fig-0001){ref-type="fig"}d).

![Kaplan--Meier curves showing progression‐free survival (PFS) in patients treated with (**a**) stereotactic body radiotherapy (SBRT) or (**b**) metastasectomy according to the presence of synchronous metastases (![](TCA-9-1671-g007.jpg "image")) no, (![](TCA-9-1671-g009.jpg "image")) yes, (![](TCA-9-1671-g001.jpg "image")) no‐censored, and (![](TCA-9-1671-g005.jpg "image")) yes‐censored. (**c**) PFS in patients with absent or (**d**) present synchronous metastases according to whether they underwent SBRT or metastasectomy (![](TCA-9-1671-g002.jpg "image")) SBRT, (![](TCA-9-1671-g008.jpg "image")) metastasectomy, (![](TCA-9-1671-g003.jpg "image")) SBRT‐censored, and (![](TCA-9-1671-g006.jpg "image")) metastasectomy‐censored.](TCA-9-1671-g004){#tca12880-fig-0001}

Among patients treated with SBRT, those with synchronous metastases exhibited significantly poorer OS than those without (*P* = 0.026) (Fig [2](#tca12880-fig-0002){ref-type="fig"}a); the difference in OS was not significant for those who underwent metastasectomy (*P* = 0.554) (Fig [2](#tca12880-fig-0002){ref-type="fig"}b). When stratified according to the presence of synchronous metastases, there was no significant difference in OS according to the type of treatment applied (*P* = 0.598 and *P* = 0.273 for SBRT and metastasectomy, respectively) (Fig [2](#tca12880-fig-0002){ref-type="fig"}c,d).

![Kaplan--Meier curves showing overall survival (OS) in patients treated with (**a**) stereotactic body radiotherapy (SBRT) or (**b**) metastasectomy according to the presence of synchronous metastases (![](TCA-9-1671-g007.jpg "image")) no, (![](TCA-9-1671-g009.jpg "image")) yes, (![](TCA-9-1671-g001.jpg "image")) no censored, and (![](TCA-9-1671-g005.jpg "image")) yes‐censored. (**c**) OS in patients with absent or (**d**) present synchronous metastases according to whether they underwent SBRT or metastasectomy (![](TCA-9-1671-g002.jpg "image")) SBRT, (![](TCA-9-1671-g008.jpg "image")) metastasectomy, (![](TCA-9-1671-g003.jpg "image")) SBRT‐censored, and (![](TCA-9-1671-g006.jpg "image")) metastasectomy‐censored.](TCA-9-1671-g010){#tca12880-fig-0002}

Toxicity {#tca12880-sec-0013}
--------

Radiation pneumonitis developed in 18 of the 21 patients who received SBRT (85.7%): grade 1 in 12 (57.1%), grade 2 in 5 (23.8%), and grade 3 in 1 (4.8%). Two patients each experienced grade 1 and 2 rib fractures, while one and two patients experienced grade 1 and 2 chest wall pain, respectively.

In the metastasectomy group, one patient experienced acute bleeding requiring surgical intervention. One patient had acute respiratory distress syndrome requiring intensive medical care; the patient improved after one month of hospitalization. One patient experienced grade 3 nausea and required fluid treatment.

Discussion {#tca12880-sec-0014}
==========

In this study, PFS was significantly longer in patients who had undergone metastasectomy than in patients who had received SBRT for pulmonary metastases. There were no significant differences in local control or OS between the treatment groups. Subgroup analysis showed that PFS rates varied depending on the presence or absence of synchronous metastases; however, the treatment method did not make a difference in either situation. OS rates showed similar trends to PFS. Multivariate analysis revealed that the presence of synchronous metastases significantly influenced PFS. No severe treatment‐related toxicities were observed in this study.

Previous studies investigating treatment outcomes in patients with pulmonary metastases were retrospective reviews of patients treated with a single modality for primary cancers of diverse origins.[19](#tca12880-bib-0019){ref-type="ref"}, [20](#tca12880-bib-0020){ref-type="ref"}, [21](#tca12880-bib-0021){ref-type="ref"} Surgery is initially recommended for the local treatment of pulmonary metastases.[14](#tca12880-bib-0014){ref-type="ref"}, [22](#tca12880-bib-0022){ref-type="ref"} The indications for treatment via metastasectomy have been relatively well studied compared to SBRT, and include good PS, long disease‐free survival, and the absence of synchronous metastases.[23](#tca12880-bib-0023){ref-type="ref"} Surgery is not recommended when incomplete resection is predicted, the primary tumor is not locoregionally controlled, widespread metastatic cancer is present, and/or pulmonary function is inadequate. A systematic review found that the two‐year OS for patients who undergo complete resection ranges from 64--88% and that the survival outcome is good.[13](#tca12880-bib-0013){ref-type="ref"} The patients in our study who underwent metastasectomy showed a two‐year OS rate of 81.8%, which was consistent; however, OS rates were poor when synchronous metastases were present.

Stereotactic body radiotherapy is increasingly being used as a local treatment for pulmonary metastases because of its noninvasiveness and lower morbidity. This modality is also considered for metastatic lesion control and disease progression delay during breaks from chemotherapy. However, studies of SBRT are subject to selection bias as they often include older patients with poor PS and pulmonary function, and higher metastatic burdens compared to patients who undergo surgery. Nevertheless, the one‐year local control rates reportedly range from 70% to 95%, which are favorable.[24](#tca12880-bib-0024){ref-type="ref"} Patients in our study also showed good one and two‐year local control rates of 83.5% and 75.2%, respectively.

Conversely, the two‐year OS rates vary in the literature, ranging from 33% to 80%.[19](#tca12880-bib-0019){ref-type="ref"} In our study, the two‐year OS was 68.2%, which is consistent with previous results despite the heterogeneous primary tumors in our patients.

Comparative retrospective investigations that compare pulmonary metastasectomy to SBRT are rare, with only two such studies published. Widder *et al*. compared metastasectomy to SBRT in patients treated in a university hospital‐based multidisciplinary setting.[14](#tca12880-bib-0014){ref-type="ref"} Patients with favorable prognoses were offered metastasectomy, while SBRT was the second treatment of choice; however, survival rates were comparable in both populations. The one, three, and five‐year OS rates were 87%, 62%, and 41% for metastasectomy, and 98%, 60%, and 49% for SBRT, respectively. The other study compared the survival outcomes of surgery versus SBRT in patients with pulmonary oligometastases from colorectal cancer.[22](#tca12880-bib-0022){ref-type="ref"} The one and two‐year OS rates were 89% and 77% for SBRT and 96% and 82% for surgery, respectively, with no significant differences. Patients who received SBRT in our study also showed comparable survival outcomes at two years to those who underwent metastasectomy. Additionally, despite the prevalence of larger‐size metastatic lesions and the presence of synchronous metastases (which are usually considered relative contraindications for metastasectomy) in the SBRT group, the survival outcomes in these patients were comparable to those in the surgery group.

Randomized trials are required to determine whether SBRT improves local control, PFS, and OS in patients with pulmonary metastases. Recently, a multicenter, randomized phase II study was performed to assess the effect of local consolidative therapy in oligometastatic non‐small cell lung cancer patients.[25](#tca12880-bib-0025){ref-type="ref"} Although the primary treated lesion was in the lung, local consolidative therapy (mainly radiotherapy) extended patients' PFS rates. To the best of our knowledge, no studies have compared active monitoring and SBRT for pulmonary metastases; however, a randomized trial comparing the outcomes of colorectal cancer patients receiving active monitoring versus those undergoing pulmonary metastasectomy has been ongoing since 2010 (NCT01106261), with the results pending.

Tanadini‐Lang *et al*. evaluated prognostic factors for OS and developed a nomogram aimed at predicting OS after SBRT for pulmonary metastases.[11](#tca12880-bib-0011){ref-type="ref"} According to their study, OS was influenced by the size of the pulmonary metastatic lesion, whether synchronous metastasis was present, and whether the primary lesion was controlled. Although patients with large metastatic lesions and synchronous metastases (which are considered contraindications to metastasectomy) were more prevalent in the SBRT group in our study, their OS rates were comparable to those in the surgery group. Thus, SBRT is considered a good local treatment modality with a broader indication than metastasectomy.

It has been suggested that SBRT may produce anti‐tumor effects not only through direct DNA damage but also via immunologic modulation. The effect of SBRT in the tumor stroma or outside the treatment field, referred to as the abscopal effect, is currently undergoing rigorous research.[26](#tca12880-bib-0026){ref-type="ref"} Widder *et al*. unexpectedly showed that although patients with good prognoses were included in the surgery instead of the SBRT group, survival outcomes were not superior in the former group.[14](#tca12880-bib-0014){ref-type="ref"} The authors explained that the high local control attained with both treatments may contribute to achieving comparable survival outcomes; however, immunologic responses may also promote favorable outcomes in patients receiving SBRT. Likewise, patients with poor prognostic factors in our study who were treated with SBRT may have benefited from immunologic responses that may have improved the survival outcomes to the extent that they were on par with those in the surgery group.

The present study had inevitable limitations as a result of its retrospective design. Additionally, the number of patients included in each treatment group was small, and the follow‐up period was short. There was also an imbalance in patient characteristics and toxicity profiles that could have biased the results.

Our study showed that local treatment of pulmonary metastases with SBRT or metastasectomy produced similar local control and OS rates. SBRT is considered a suitable local modality, and a wide patient pool is eligible for this treatment. However, patients with synchronous metastases are only likely to obtain a small benefit from local treatment, whether via SBRT or surgery.
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